Bcr-Abl inhibitors (TargeGen)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameBcr-Abl inhibitors (TargeGen)
Drug Alias NameBcr-Abl inhibitors (TargeGen)TG-101114TG-101113
ClassificationSmall molecules
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitorsAnticancer protein kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTargegen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTargegen Inc
Active IndicationsN/A
Inactive IndicationsLeukemia, Myelogenous, Chronic

Other Information

ATC CodeN/A
Related LinksN/A